Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LPO | P22079 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16107858 | 0.84 | CHRNB2 (0.36) | CHRNB2CHRNA4KMT2ALPOMCL1 | |
| SCHEMBL1681801 | 0.80 | FPR2 (0.33) | KMT2ADRD2DRD4DRD3DRD1 | |
| SCHEMBL459536 | 0.78 | CHRNB2 (0.40) | CHRNB2CHRNA4KMT2ALPOFDPS | |
| SCHEMBL2830180 | 0.77 | ALDH1A1 (0.46) | KMT2ADRD2DRD4DRD3DRD1 | |
| SCHEMBL1681893 | 0.76 | LMNA (0.37) | — | |
| SCHEMBL4620124 | 0.75 | TLR8 (0.31) | CHRNB2CHRNA4KMT2A | |
| SCHEMBL3914898 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4KMT2ALPOFDPS | |
| SCHEMBL5694205 | 0.74 | L3MBTL1 (0.40) | KMT2AFDPSMEN1 | |
| SCHEMBL10739013 | 0.72 | KMT2A (0.38) | CHRNB2CHRNA4KMT2AMEN1 | |
| SCHEMBL3016928 | 0.71 | KMT2A (0.44) | CHRNB2CHRNA4KMT2ALPOMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023165966-A1 | PRESSURE-SENSITIVE ADHESIVE COMPOSITION | TESA SE (DE) | 2023-09-07 | — | — | WO | claimed |
| CN-111435705-B | Repairing agent and repairing method thereof and method for preparing photoelectric film | 杭州纤纳光电科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-107710462-B | Electrochemical hydrogen storage electrode and battery | 巴斯夫公司 | 2022-08-02 | — | — | CN | claimed |
| CN-113430594-B | Application of nitrogen-containing micromolecules and electroplating solution | 季华实验室 | 2022-04-01 | — | — | CN | claimed |
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY INC (US) | 2021-12-23 | — | — | US | claimed |
| CN-107615556-B | Electrolyte and metal hydride battery | 巴斯夫公司 | 2021-11-02 | — | — | CN | claimed |
| CN-113214795-A | Preparation method of ionic liquid phase-change microcapsule | 中国科学院过程工程研究所 | 2021-08-06 | — | — | CN | claimed |
| US-20130341561-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY, INC. (US) | 2013-12-26 | — | — | US | claimed |
| US-8083945-B2 | Fluid storage and purification method and system | MATHESON TRI-GAS, INC. (US) | 2011-12-27 | — | — | US | claimed |
| US-20100223208-A1 | FLUID STORAGE AND PURIFICATION METHOD AND SYSTEM | MATHESON TRI-GAS, INC. (US) | 2010-09-02 | — | — | US | claimed |
| US-7718579-B2 | Electrochemical deblocking using a hydrazine derivative | COMBIMATRIX CORPORATION (US) | 2010-05-18 | — | — | US | claimed |
| WO-2009126382-A2 | SUPERCAPACITORS AND METHODS OF MAKING AND USING SAME | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-10-15 | — | — | WO | claimed |
| EP-1869061-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | Combimatrix Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1805206-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | Combimatrix Corporation (US) | 2007-07-11 | — | — | EP | claimed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | claimed |
| WO-2006105037-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | COMBIMATRIX CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | claimed |
| US-20240101999-A1 | HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS | THERMO FISHER SCIENTIFIC GENEART GMBH (DE) | 2024-03-28 | — | — | US | disclosed |
| WO-2002014340-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES_______________ | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | DNMT1, DNASE1, DNPEP | CHRNB2 361/4885CHRNA4 1202/4885KMT2A 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.